PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.97M | 12.60M | 9.92M | 6.96M | 4.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.97M | 12.60M | 9.92M | 6.96M | 4.17M |
| Cost of Revenue | 9.03M | 7.59M | 6.03M | 4.26M | 2.60M |
| Gross Profit | 5.95M | 5.01M | 3.89M | 2.70M | 1.57M |
| SG&A Expenses | 6.17M | 4.63M | 4.08M | 3.21M | 2.53M |
| Depreciation & Amortization | 673.50K | 565.10K | 459.30K | 339.40K | 208.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.87M | 12.78M | 10.56M | 7.80M | 5.34M |
| Operating Income | -898.70K | -186.30K | -641.90K | -845.00K | -1.17M |
| Income Before Tax | -611.90K | 217.10K | -188.30K | -458.00K | -860.50K |
| Income Tax Expenses | 419.10K | 99.10K | 113.40K | -1.00K | -76.10K |
| Earnings from Continuing Operations | -1.03 | 0.12 | -0.30 | -0.46 | -0.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.40K | 5.10K | 19.70K | 17.30K | 25.90K |
| Net Income | -1.07M | 123.00K | -282.10K | -439.90K | -758.70K |
| EBIT | -898.70K | -186.30K | -641.90K | -845.00K | -1.17M |
| EBITDA | -225.00K | 294.40K | -248.60K | -563.60K | -837.60K |
| EPS Basic | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 500.55M | 469.43M | 465.29M | 403.64M | 306.62M |
| Average Diluted Shares Outstanding | 500.55M | 469.43M | 465.29M | 403.64M | 306.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |